DAF reports provision of study materials from Pierre Fabre; research grants from Aldeyra, Astex Therapeutics, Bayer, Boehringer Ingelheim, and RS Oncology; consulting fees from Atara Therapeutics, Bristol-Myers Squibb, Novocure, Cambridge Clinical Labs, Sciensus, and Targovax; honoraria from Boehringer Ingelheim, Sciensus, and Chorus Group; payment for expert testimony from Leigh Day; conference fees from Janssen; board role with IASLC; and research support from AstraZeneca, Bergen Bio, Clovis, Eli Lilly, FujiBio, GlaxoSmithKline, Imagen Therapeutics, MSD, Pierre Fabre, and Roche. GG reports research grants to their institution from Bristol-Myers Squibb, Janssen-Cilag, Novartis, AstraZeneca, Astex, Roche, Heartflow, and Biontech; and consulting fees from AstraZeneca. CO reports grants to their institution from Bristol-Myers Squibb; and speaker fees from Bristol-Myers Squibb. GGH reports consulting fees and honoraria from AstraZeneca. PS reports research grants from BLT Charity and Polaris Pharma; honoraria from RS Oncology and Merck Serono; travel fees from MSD; and board role in the NCRI Mesothelioma subgroup. SD and MN declare no competing interests.